Alvotech (ALVO) earnings call transcripts

Management framed the half as a supply-constrained transition, with manufacturing restored to plan and execution now focused on rebuilding inventory and preparing launches.

Management framed 2026 as an execution year, prioritizing FDA remediation, reliable supply, partner-led launches, and selective manufacturing diversification.

Management framed the call around a delayed Symphony approval and a deliberate production slowdown, while emphasizing that launch momentum and 2026 growth remain intact.